Capricor Therapeutics Dividendos y recompras
Dividendo controles de criterios 0/6
Capricor Therapeutics no tiene historial de pago de dividendo.
Información clave
n/a
Rentabilidad por dividendo
-49.3%
Rendimiento de la recompra
| Rendimiento total para el accionista | -49.3% |
| Rendimiento futuro de los dividendos | n/a |
| Crecimiento de los dividendos | n/a |
| Próxima fecha de pago de dividendos | n/a |
| Fecha ex dividendo | n/a |
| Dividendo por acción | n/a |
| Ratio de pago | n/a |
Últimas actualizaciones de dividendos y recompras
No hay actualizaciones
Recent updates
Actualización de narrativa • Sep 08
CAPR: November FDA Decision On Refined Upper Limb Indication Will Drive Upside Potential
Capricor Therapeutics' updated analyst price target of $54, up from $28, reflects a shift toward higher implied valuation as analysts factor in the FDA's acceptance of deramiocel's major amendment, the extended action date to November 22, and the possibility of a refined upper limb function indication despite ongoing regulatory risk flagged in recent research. Analyst Commentary Recent research on Capricor Therapeutics highlights a wide range of views, but several bullish analysts point to a clearer regulatory path for deramiocel and a reset in valuation expectations after new FDA interactions.Seeking Alpha • Sep 03
Capricor: Downgrade To Hold On Deramiocel PDUFA Extension And DMD Change
Summary Capricor Therapeutics, Inc. is downgraded from Buy to Hold due to regulatory setbacks for deramiocel in Duchenne Muscular Dystrophy [DMD]. An FDA Advisory Committee voted primarily against deramiocel's approval for DMD cardiomyopathy, increasing regulatory risk despite prior positive Phase 3 HOPE-3 data. CAPR is now pursuing FDA review for deramiocel in a new proposed indication—upper limb function in DMD—with a revised PDUFA date of November 22, 2026. While the primary endpoint was met and new data submitted for upper limb function, the major amendment classification and extended review timeline heighten uncertainty and increases risk. Read the full article on Seeking AlphaActualización de narrativa • Aug 25
CAPR: November FDA Decision On Refined Duchenne Indication Will Drive Upside Potential
Capricor Therapeutics’ analyst fair value estimate has reset from $63.00 to $28.00 as analysts factor in a higher discount rate, a lower assumed future P/E multiple, and continued regulatory uncertainty around deramiocel, despite the new HOPE-3 open-label extension data. Analyst Commentary Recent Street research around Capricor Therapeutics highlights a sharp divergence in views, with most firms reacting cautiously to the negative advisory committee outcome for deramiocel and the extended regulatory timeline, while a smaller group of bullish analysts sees potential valuation upside if the refined indication and new data package gain traction with regulators.
Actualización de narrativa • Aug 11
CAPR: Post AdCom Regulatory Outcome Will Drive 2026 Upside Potential
Capricor Therapeutics now carries a sharply reduced analyst price target of about $4.38, down from roughly $49.44, as analysts factor in the negative deramiocel AdCom vote, heightened FDA approval concerns, higher perceived risk, and lower projected profitability and P/E multiples. Analyst Commentary Recent research on Capricor Therapeutics has shifted sharply after the deramiocel advisory committee outcome, with most firms now focused on regulatory risk, legal overhangs, and reduced earnings potential.Actualización de narrativa • Jul 27
CAPR: July FDA Panel Vote Will Determine Bullish 2026 Approval Path
Capricor Therapeutics' analyst fair value estimate has been reduced from $54.67 to $49.44, as analysts factor in sharply lower price targets following critical FDA briefing documents on deramiocel, multiple downgrades to Neutral ratings, and increased concern that current data and statistical protocols may not support approval in its present form. Analyst Commentary Recent Street research on Capricor Therapeutics highlights a sharp reassessment of risk around deramiocel ahead of the upcoming FDA advisory committee meeting, with price targets and ratings moving in response to concerns over data integrity, statistical methods, and regulatory pushback.
Nueva narrativa • Jul 12
The Exosome Pioneer: Why Capricor (CAPR) is Poised for an August FDA Breakthrough
Prologue: Witnessing the Exosome Revolution in Clinical Practice As a veterinarian actively running a clinic in 2026, I have seen firsthand the disruptive power of exosome technology. Last year, I introduced an 'exosome ice-needling injection machine' at my hospital to treat some of the most stubborn conditions in small animals.Actualización de narrativa • Jun 15
CAPR: August FDA Decision On Duchenne Therapy Will Drive Long Term Upside Potential
Capricor Therapeutics' analyst price target has been cut by $5, to $38 from $43, as analysts factor in the removal of an expected $80 million milestone payment linked to the NS Pharma dispute and a later modeled U.S. launch for Deramiocel. Analyst Commentary Bullish analysts are recalibrating their models around the NS Pharma dispute and timing of the Deramiocel U.S. launch, yet some still see meaningful potential tied to upcoming regulatory and monetization events.
Actualización de narrativa • Jun 01
CAPR: FDA Decision And HOPE-3 Data Will Drive Bullish Repricing
Analysts have trimmed their average price target on Capricor Therapeutics by about $1.60 to roughly $39.40. This reflects adjustments for the removed $80m milestone and a later modeled Deramiocel U.S. launch, while still factoring in upcoming FDA decisions and related catalysts.Actualización de narrativa • May 15
CAPR: August PDUFA Decision Will Shape Duchenne Treatment Adoption Outlook
Narrative Update: Capricor Therapeutics Analyst Price Target Shift The analyst price target for Capricor Therapeutics has been reduced by $5 to $38, as analysts factor in the removal of an expected $80 million milestone payment and a later modeled U.S. launch for Deramiocel following the company’s legal action against NS Pharma. Analyst Commentary Recent Street research around Capricor Therapeutics has shifted from purely optimistic toward a more balanced stance, as bullish analysts factor in both regulatory progress for Deramiocel and the impact of the company’s legal action against NS Pharma.Actualización de narrativa • Apr 29
CAPR: August PDUFA Cardiac Data Will Drive Bullish 2026 Approval Setup
Narrative Update: Capricor Therapeutics The updated analyst price target framework for Capricor Therapeutics moves from a prior fair value of $50.80 to $54.67. This reflects analysts' use of higher projected revenue growth, wider profit margins and a higher future P/E multiple following recent positive deramiocel data, FDA review progress and a series of target increases across the Street.Actualización de narrativa • Apr 15
CAPR: August PDUFA Decision Will Drive Bullish Duchenne Thesis
Analysts have lifted their average price targets on Capricor Therapeutics into a $41 to $63 range, supported by recent FDA progress on deramiocel for Duchenne muscular dystrophy, additional positive Phase 3 HOPE-3 data, and updated cash and review timelines that feed into modest tweaks to discount rate, revenue growth, profit margin, and future P/E assumptions in the valuation model. Analyst Commentary Bullish analysts are largely framing recent volatility in Capricor Therapeutics as a short-term shakeout rather than a shift in the long-term story.Actualización de narrativa • Apr 01
CAPR: August PDUFA And HOPE 3 Readout Will Shape Bullish Case
Analysts have lifted their blended price target on Capricor Therapeutics to $63, supported by higher targets from several firms. These firms point to recent FDA milestones for deramiocel in Duchenne muscular dystrophy, additional Phase 3 HOPE-3 data, and updated PDUFA timing as key drivers behind their refreshed assumptions.Actualización de narrativa • Mar 18
CAPR: August PDUFA Decision And HOPE 3 Data Will Drive Bullish Outlook
Narrative Update on Capricor Therapeutics The analyst fair value estimate for Capricor Therapeutics has moved from $62.00 to $63.00, reflecting updated Street research that points to higher price targets tied to recent FDA progress for deramiocel in Duchenne muscular dystrophy and supportive Phase 3 HOPE-3 data. Analyst Commentary Recent Street research has been broadly constructive on Capricor Therapeutics, with bullish analysts highlighting regulatory milestones for deramiocel in Duchenne muscular dystrophy and updated Phase 3 HOPE-3 data as key drivers behind their views.Actualización de narrativa • Mar 03
CAPR: HOPE 3 Data And BLA Resubmission Will Drive Bullish 2026 Approval Path
Analysts now place a slightly higher implied value on Capricor Therapeutics, with their updated price target moving to $62.00. This is supported by modest tweaks to the discount rate, revenue growth assumptions, and long-term profit margin and P/E inputs.Actualización de narrativa • Feb 17
CAPR: HOPE-3 Regulatory Progress And Capital Raise Will Drive Bullish Repricing
Analysts have kept their $41.00 price target for Capricor Therapeutics unchanged, citing only minor model adjustments such as slightly different discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News Capricor provided a regulatory update on its Biologics License Application for Deramiocel in Duchenne muscular dystrophy, with the FDA requesting the full Phase 3 HOPE-3 clinical study report and supporting data to address a Complete Response Letter, without asking for additional clinical studies or new patient data.Actualización de narrativa • Feb 03
CAPR: Phase 3 Duchenne Cardiac Results Will Shape Bullish 2026 Approval Path
Narrative Update The analyst price target for Capricor Therapeutics has moved from about US$44.56 to US$50.80, with analysts pointing to expectations around Phase 3 HOPE-3 data for Deramiocel in Duchenne muscular dystrophy cardiomyopathy and updated modeling assumptions as key drivers of the change. Analyst Commentary Recent Street research points to a change in how some analysts are framing risk and potential reward around Capricor Therapeutics, especially with Phase 3 HOPE-3 data for Deramiocel in Duchenne muscular dystrophy cardiomyopathy expected in Q4.Actualización de narrativa • Jan 20
CAPR: HOPE 3 Cardiac Outcome Data Will Shape Bullish Mid 2026 Approval Path
The analyst price target for Capricor Therapeutics has increased from $12 to $13, as analysts incorporate updated assumptions for Deramiocel approval in Duchenne muscular dystrophy cardiomyopathy and anticipated Phase 3 HOPE-3 cardiac outcome data. Analyst Commentary Bullish analysts are framing the price target move to US$13 as a reflection of updated expectations around Deramiocel in Duchenne muscular dystrophy cardiomyopathy rather than a broad shift in the overall story.Actualización de narrativa • Jan 06
CAPR: HOPE-3 Duchenne Cardiac Data Will Drive Bullish Repricing
Analysts have lifted their fair value estimate for Capricor Therapeutics from $12.00 to $41.00 per share, citing updated assumptions around Deramiocel approval prospects in Duchenne muscular dystrophy cardiomyopathy, following recent Street research and price target revisions. Analyst Commentary Recent Street commentary around Capricor Therapeutics has centered on expectations for Deramiocel in Duchenne muscular dystrophy cardiomyopathy, with valuation work closely tied to regulatory outcomes and clinical readouts for the Phase 3 HOPE-3 trial anticipated in Q4.Actualización de narrativa • Dec 19
CAPR: Mid 2026 Approval Path Will Drive HOPE 3 Cardiac Catalyst Narrative
Analysts have sharply increased their price target for Capricor Therapeutics, effectively more than doubling fair value from approximately $29 to about $62. They cite higher projected revenue growth, a dramatic improvement in long term profit margins, a more normalized future earnings multiple, and growing confidence that positive HOPE-3 data could support regulatory flexibility and keep a potential Deramiocel approval on track for mid 2026.Actualización de narrativa • Dec 05
CAPR: Phase 3 Duchenne Cardiac Data Will Drive 2026 Approval Hopes
Analysts have sharply raised their price target on Capricor Therapeutics, with the modeled fair value estimate climbing from about $20.60 to roughly $44.56 per share. They cite stronger expected revenue growth, significantly improved profit margins, and increasing confidence that positive HOPE-3 Phase 3 data could support Deramiocel approval for Duchenne muscular dystrophy cardiomyopathy on an accelerated mid 2026 timeline.Artículo de análisis • Nov 05
We're Not Very Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Artículo de análisis • Sep 09
Capricor Therapeutics, Inc. (NASDAQ:CAPR) May Have Run Too Fast Too Soon With Recent 30% Price Plummet
To the annoyance of some shareholders, Capricor Therapeutics, Inc. ( NASDAQ:CAPR ) shares are down a considerable 30...Artículo de análisis • Jun 24
Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
To the annoyance of some shareholders, Capricor Therapeutics, Inc. ( NASDAQ:CAPR ) shares are down a considerable 25...Artículo de análisis • May 16
Here's Why We Think Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO Compensation Looks Fair
Key Insights Capricor Therapeutics to hold its Annual General Meeting on 22nd of May CEO Linda Marbán's total...Estabilidad y crecimiento de los pagos
Obteniendo datos sobre dividendos
Dividendo estable: No hay datos suficientes para determinar si los dividendos por acción de CAPR han sido estables en el pasado.
Dividendo creciente: Datos insuficientes para determinar si los pagos de dividendos de CAPR han aumentado.
Rentabilidad por dividendo vs. Mercado
| Rentabilidad por dividendo de Capricor Therapeutics vs. Mercado |
|---|
| Segmento | Rentabilidad por dividendo |
|---|---|
| Empresa (CAPR) | n/a |
| Suelo de mercado 25% (US) | 1.4% |
| Techo de mercado 25% (US) | 4.1% |
| Media de la industria (Biotechs) | 2.2% |
| Analista de previsiones (CAPR) (hasta 3 años) | n/a |
Dividendo destacado: No es posible evaluar la rentabilidad por dividendo de CAPR en comparación con el 25% inferior de los pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.
Alto dividendo: No es posible evaluar la rentabilidad por dividendo de CAPR en comparación con el 25% de los principales pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.
Pago de beneficios a los accionistas
Cobertura de los beneficios: No hay datos suficientes para calcular el ratio de pago de CAPR para determinar si sus pagos de dividendos están cubiertos por los beneficios.
Pago en efectivo a los accionistas
Cobertura de flujo de caja: No es posible calcular la sostenibilidad de los dividendos, ya que CAPR no ha comunicado ningún pago.
Descubre empresas que pagan buenos dividendos
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/09/15 08:33 |
| Precio de las acciones al final del día | 2026/09/15 00:00 |
| Beneficios | 2026/06/30 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Capricor Therapeutics, Inc. está cubierta por 10 analistas. 10 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Matthew Venezia | Alliance Global Partners |
| Madison Wynne El-Saadi | B. Riley Securities, Inc. |
| Kristen Kluska | Cantor Fitzgerald & Co. |